Destruction of the rainforest increased by 9.5% compared to the previous 12 months, new data shows.
Manchester United welcome Paris Saint-Germain on Wednesday night in what is arguably the tie of Champions League matchday 5. United have already beaten last season’s finalists once this season, with Marcus Rashford’s late goal in Paris getting the Red Devils off to a perfect start in Group H. Ole Gunnar Solskjaer’s side then thrashed RB Leipzig 5-0 to leave themselves odds-on to reach the last-16, but only picked up three points from their double-header against Istanbul Basaksehir after losing in Turkey.
Santa Fe, NM, Nov. 30, 2020 (GLOBE NEWSWIRE) -- The International Folk Art Market (IFAM), the world’s largest folk art market, is hosting a winter virtual market December 2 – 6. The event features 27 first-time IFAM artists from Colombia, Ghana, Guatemala, India, Mexico, Peru, Ukraine and Uzbekistan. The artists, among other new Market participants, had been selected to participate in the summer event, that was canceled due to the COVID-19 pandemic. The 2020 cohort of Market artists have all been invited to return to IFAM’s next Market offering. The new work includes baskets, apparel, home textiles, jewelry, ceramics and 3D pieces.“This is the first time these artists’ work will be available at IFAM,” said Stuart Ashman, IFAM CEO. “Their body of work is incredible, and we are thrilled to unveil it at this year’s winter event.”One of the premier first-time artists is Pachan Premjibhai Siju. From India, he incorporates contemporary styles with the craftsmanship of the elders to produce one-of-a-kind shawls. His weavings tell the story of climate change on the world as a whole and the tradition of weaving. “I have been thinking about climate change,” he said. “Our original products were sustainable, but today commercial work often is not. I wanted to create work that is contemporary and sustainable.”See more about Siju and his work at: http://ifamstories.org/artists/pachan-premjibhai-siju/A father-son team are also first-time artists. From Usbekistan, Bakhtiyor and Diyorbek Nazirov both began their crafts at the age of 12. The process of making traditional Rishtan ceramics has remained mostly unchanged for more than 800 years. The Nazirovs are known for their intricate designs in blue and turquoise which, according to ancient beliefs, are the colors of pure water and cloudless sky, symbolizing happiness.See more about their work at: http://ifamstories.org/artists/bakhtiyor-nazirov-diyorbek-nazirov/The IFAM winter market items are available for preview until the market opens on December 2. Go to IFAM for more information. CONTACT: Joanie Griffin International Folk Art Market 505-261-4444 email@example.com
Although the fall of the retail group puts 13,000 jobs at risk, there will be no immediate redundancies.
The collapse of Topshop owner Arcadia could mean thousands of pension holders take a hit.
The owner of Dove soap and Ben & Jerry's ice cream is testing a shorter week in New Zealand.
Timeline: the rise and fall of Philip Green. Knighted in 2006 and once worth £4.9bn, Green became the ‘unacceptable face of capitalism’
Glass Bottle Packaging Market is poised to experience spend growth of more than USD 13 billion between 2020-2024 at a CAGR of over 4.19%.
ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia
GUANGZHOU, China, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd (“Viomi” or the “Company”) (NASDAQ: VIOT), a leading IoT @ Home technology company in China, today announced that Mr. Shun Jiang has tendered his resignation as Chief Financial Officer of the Company for personal reasons, effective immediately. The Company has commenced the search for Mr. Jiang’s replacement and is committed to moving quickly to fill the role. The Company’s finance team will report to Mr. Xiaoping Chen, Founder, Chairman of the Board of Directors and Chief Executive Officer of Viomi, in the interim. Mr. Xiaoping Chen commented, “On behalf of the Board of Directors and management team, I want to thank Mr. Jiang for his contributions to Viomi and wish him all the best in his future endeavors.”About Viomi TechnologyViomi’s mission is to redefine the future home via the concept of IoT @ Home.Viomi has developed a unique IoT @ Home platform consisting an ecosystem of innovative IoT-enabled smart home products, together with a suite of complementary consumable products and value-added businesses. This platform provides an attractive entry point into the consumer home, enabling consumers to intelligently interact with a broad portfolio of IoT products in an intuitive and human-like manner to make daily life more convenient, efficient and enjoyable, while allowing Viomi to grow its household user base and capture various additional scenario-driven consumption events in the home environment.For more information, please visit: http://ir.viomi.com.Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as Viomi’s strategic and operational plans, contain forward-looking statements. Viomi may also make written or oral forward-looking statements in its periodic reports to the United States Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company’s growth strategies; the cooperation with Xiaomi, the recognition of the Company’s brand; trends and competition in global IoT-enabled smart home market; development and commercialization of new products, services and technologies; governmental policies relating to the Company’s industry and general economic conditions in China and around the globe, and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.For investor and media inquiries, please contact:In China:Viomi Technology Co., Ltd Cecilia Li E-mail: firstname.lastname@example.orgThe Piacente Group, Inc. Emilie Wu Tel: +86-21-6039-8363 E-mail: email@example.comIn the United States:The Piacente Group, Inc. Brandi Piacente Tel: +1-212-481-2050 E-mail: firstname.lastname@example.org
Michael Mettee has been named chief financial officer of FirstBank and its parent company, FB Financial Corporation (NYSE:FBK). He was appointed interim CFO in April and previously served as CFO/Banking and director of Capital Markets.
LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Evercore ISI 3rd Annual HealthCONx Conference at 10:05 a.m. ET on December 3, 2020. A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. A replay of the webcast will be available for approximately 90 days following the presentation.About MeiraGTx MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.For more information, please visit www.meiragtx.com.Contacts Investors: MeiraGTx email@example.comMedia: W2O pure Christiana Pascale (212) 257-6722 firstname.lastname@example.org
* MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expenses * EVERSANA may earn revenue share payments over five years subject to predefined cap * MacroGenics’ projected cash runway remains into 2023ROCKVILLE, MD and CHICAGO, IL, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has partnered with EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the United States, if approved.Margetuximab is an investigational, monoclonal antibody derived from MacroGenics’ proprietary Fc-Optimization technology platform. A Biologics License Application (BLA) for margetuximab for the treatment of patients with pre-treated metastatic HER2-positive breast cancer in combination with chemotherapy is under review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) goal date of December 18, 2020.“We believe that margetuximab, if approved, could become a valuable treatment option for patients living with this devastating disease,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “We are excited to partner with EVERSANA and leverage their integrated commercial services to efficiently launch margetuximab. We have been working closely with EVERSANA to fully align our commercialization strategies to educate healthcare providers and ensure patient access to margetuximab, while maintaining MacroGenics’ cash runway to fund our broader portfolio.”Jim Lang, CEO of EVERSANA, added, “We’ve built a suite of comprehensive commercial services for biopharmaceutical innovators like MacroGenics and look forward to entering this risk-sharing arrangement with MacroGenics to support the commercialization of margetuximab, if approved. Our partnership with MacroGenics puts the patient first by supporting broad market access and comprehensive patient support services. We will work closely with MacroGenics on each stage of the product launch and roll-out.”Under the terms of the agreement, MacroGenics maintains ownership of margetuximab, including all manufacturing, regulatory and development responsibilities for the product. This includes MacroGenics’ continued development of margetuximab in combination with immune checkpoint inhibitors in gastroesophageal cancer in the Phase 2/3 MAHOGANY study, as well as other ongoing studies. EVERSANA receives a co-exclusive right to conduct approved commercialization activities. EVERSANA will utilize its internal capabilities to support sales and marketing, market access, channel management services, data and analytics, medical affairs, and other patient access related services. MacroGenics will book sales for margetuximab. Upon the potential approval of margetuximab, EVERSANA and MacroGenics will equally share in funding EVERSANA’s commercialization expenses. In exchange for co-funding these expenses, EVERSANA will earn future revenue share payments which shall be capped at 125% of EVERSANA’s cumulative service fees. The term of the agreement is five years following the date of FDA approval, subject to predefined termination provisions.About HER2-Positive Breast Cancer Human epidermal growth factor receptor 2 (HER2) is a protein found on the surface of some cancer cells that promotes growth and is associated with aggressive disease and poor prognosis. Approximately 15-20% of breast cancer cases are HER2-positive. Antibody-based therapies targeting HER2 have greatly improved outcomes of patients with HER2-positive breast cancer and are now standard of care in both early-and late-stage disease. However, metastatic breast cancer remains an area of unmet need and ongoing HER2 blockade is recommended for the treatment of patients with relapsed or refractory disease.About Margetuximab Margetuximab is an Fc-engineered, monoclonal antibody that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors. Margetuximab was designed to provide HER2 blockade and has similar HER2 binding and antiproliferative effects as trastuzumab. In addition, margetuximab has been engineered to enhance the engagement of the immune system through MacroGenics’ Fc Optimization technology. Margetuximab is also being evaluated in combination with checkpoint blockade in the Phase 2/3 MAHOGANY trial for the treatment of patients with HER2-positive gastroesophageal cancer (NCT04082364), and in combination with tebotelimab (PD-1 × LAG-3 bispecific DART® molecule) in various HER2+ indications (NCT03219268). For more information, please visit www.clinicaltrials.gov.About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.About EVERSANA™ EVERSANA™ is the leading provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life science solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.MacroGenics’ Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for MacroGenics, Inc. (the “Company”), including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19), and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. CONTACT: Contacts: MacroGenics, Inc. Jim Karrels, Senior Vice President, CFO email@example.com 1-301-251-5172 EVERSANA Sarah Zwicky firstname.lastname@example.org 1-414-434-4691
Nordson Corporation announces updates to its Board of Directors
Skillz Inc. ("Skillz"), the leading mobile games platform connecting players in fair, fun, and meaningful competition, today announced that its CEO and founder, Andrew Paradise, will participate at Wells Fargo’s 2020 Technology, Media & Telecommunications Virtual Summit being held December 1-2, 2020.
MVB Financial Corp. (NASDAQ: MVBF) ("MVB" or the "Company") announced today the completion of a private placement of $40 million of 4.25% fixed to floating rate subordinated notes due 2030 (the "Notes") to certain qualified institutional buyers. The Company intends to use the net proceeds from the sale of Notes to purchase shares of its common stock pursuant to the previously announced modified "Dutch Auction" tender offer and any remaining proceeds for general corporate purposes. The completion of the private placement of the Notes was a condition to the tender offer. This condition has now been satisfied. The Securities and Exchange Commission requires the tender offer to remain open for five additional business days subsequent to the satisfaction of the financing condition. The tender offer was commenced on November 17, 2020 and is scheduled to expire at 5:00p.m. New York City Time, on December 18, 2020, unless otherwise extended.
Zaandam, the Netherlands, November 30, 2020 – Ahold Delhaize announces today that the UFCW Locals of its U.S. brand Stop & Shop have ratified the agreement to terminate participation in the United Food & Commercial Workers International Union – Industry Pension Fund (the “National Plan”). As previously announced, the agreement does not impact the 2020 financial outlook. Details of the financial impact were outlined in the original release on July 21st, 2020, and can be found here. This withdrawal improves the security of pension benefits for associates as well as reduces financial risk for the company and was determined, by the National Plan’s trustees, to be in the best interests of the National Plan’s participants and beneficiaries. Also as previously announced, Stop & Shop, together with Kroger and the UFCW Locals, are creating the UFCW International Union-Industry Variable Annuity Pension Plan for future benefits. This new plan is designed to protect the benefit accrual of participants, with a significantly reduced risk of plan underfunding and improved visibility on annual contributions. Cautionary notice This communication includes forward-looking statements. All statements other than statements of historical facts may be forward-looking statements. Words such as impact, outlook, 2020, improve(s)/(d), reduce(s)/(d), risk, to be, interests, creating, future, plan, designed or other similar words or expressions are typically used to identify forward-looking statements. Forward-looking statements are subject to risks, uncertainties and other factors that are difficult to predict and that may cause actual results of Koninklijke Ahold Delhaize N.V. (the “Company”) to differ materially from future results expressed or implied by such forward-looking statements. Such factors include, but are not limited to the risk factors set forth in the Company’s public filings and other disclosures. Forward-looking statements reflect the current views of the Company’s management and assumptions based on information currently available to the Company’s management. Forward-looking statements speak only as of the date they are made and the Company does not assume any obligation to update such statements, except as required by law. For more information: Press office: +31 88 659 5134 Investor relations: +31 88 659 5213 Social media:Twitter: @AholdDelhaize YouTube: @AholdDelhaize LinkedIn: @Ahold-Delhaize Ahold Delhaize is one of the world’s largest food retail groups and a leader in both supermarkets and e-Commerce. Its family of great, local brands serves 54 million customers each week in Europe, the United States, and Indonesia. Together, these brands employ 380,000 associates in 6,967 grocery and specialty stores and include the top online retailer in the Benelux and the leading online grocers in the Benelux and the United States. Ahold Delhaize brands are at the forefront of sustainable retailing, sourcing responsibly, supporting local communities and helping customers make healthier choices. Headquartered in Zaandam, the Netherlands, Ahold Delhaize is listed on the Euronext Amsterdam and Brussels stock exchanges (ticker: AD) and its American Depositary Receipts are traded on the over-the-counter market in the U.S. and quoted on the OTCQX International marketplace (ticker: ADRNY). For more information, please visit www.aholddelhaize.com.
VAUGHAN, Ontario, Nov. 30, 2020 (GLOBE NEWSWIRE) -- IGNITE International Brands, Ltd. (CSE:BILZ, OTCQX: BILZF) (“IGNITE” or the “Company”), a global consumer packaged goods brand, announces that the Company filed its financial statements for the period ended September 30, 2020, interim MD&A for the same period and accompanying certificates (collectively, the “Interim Filings”) today. The Interim Filings have been filed on the System for Electronic Document Analysis and Retrieval and may be viewed by shareholders and interested parties under the Company’s profile at www.sedar.com. In the third quarter, the Company went through a major restructuring after terminating and replacing its President in June 2020. During this period, IGNITE made a number of management changes and significantly reduced non-revenue generating expenses. As a result, the loss from operations was reduced from $12.3 million in the third quarter 2019, to $1.1 million in the third quarter 2020. “Costs were brought under control in the third quarter. In the fourth quarter, Management has turned its full attention to sales,” said John Schaefer, the Company’s President and COO.Dan Bilzerian, the Company’s CEO, noted, “The Company, which is in its early growth stage, faced the customary challenges in trying to find the right management and the right partners to meet consumer demand and bring IGNITE’s high quality, innovative products to market. Underperforming partners in Canada, the United States, and the United Kingdom have been replaced; the Company has retaken control of distribution in the United States; and agreements with new distribution partners in the United States, Australia and other countries have been executed, which we expect to pave the way for sustained growth and profitability. As a result of these changes, management expects the revenue for the fourth quarter of 2020 to exceed the revenue for all three prior quarters in 2020, and for Ignite to report its first profitable quarter in the fourth quarter 2020. This will position IGNITE to finally start to realize its great potential in 2021, which we expect to be an exciting year for the Company.” About IGNITEIGNITE is a global consumer brand, operating in the premium product segment of the market. Founded by Dan Bilzerian, the Company’s ‘quality‐first’ approach is fundamental to the brand and its products. IGNITE product categories now include CBD products, nicotine and synthetic nicotine vape products, premium performance drinks named ZRO, spirits featuring a premium vodka, and apparel. The IGNITE THC product line was introduced in Canada in 2020.Shares of IGNITE are listed on the Canadian Securities Exchange (CSE) under the symbol “BILZ” and quoted in the United States on the OTCQX under the symbol “BILZF”.Further information on IGNITE can be found on the Company’s website at ignite.co.For further information, please contact:Linda K. Menzel, General Counsel Tel: 310‐867‐3859 Email: email@example.comCAUTIONARY STATEMENT REGARDING FORWARD‐LOOKING INFORMATION This news release includes certain “forward‐looking statements” under applicable Canadian securities legislation. Forward‐looking statements include, but are not limited to, statements with respect to IGNITE’s ability to achieve profitability in the fourth quarter, the benefits of the internal corporate reorganization, its ability to drive down operating costs, its ability to drive up sales growth, its ability to expand its customer base and product offering, its ability to have a successful market strategy, its ability to build strategic partnerships, its ability to bring to expand globally and its ability to improve its overall financial performance. Forward‐looking statements are necessarily based upon several estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward‐looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the effects and impacts of the coronavirus disease (COVID‐19) pandemic, the extent and duration of which are uncertain at this time on IGNITE’s business and general economic and business conditions and markets; the ability of IGNITE to give effect to its business plan; reliance on the “IGNITE” brand which may not prove to be as successful as contemplated; the ability to and risks associated with unlocking future licensing opportunities with the “IGNITE” brand, and the ability of IGNITE to capture significant market share. There can be no assurance that any of the forward‐looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐looking statements. The Company disclaims any intention or obligation to update or revise any forward‐looking statements, whether because of new information, future events or otherwise, except as required by law.CAUTION REGARDING FINANCIAL ESTIMATES The financial estimates set forth above are based on an initial review of the Company’s operations for the quarter ended December 31, 2020 and are subject to change. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to the financial estimates and other data, and accordingly does not express an opinion or any other form of assurance with respect thereto. The views expressed by management herein should not be viewed as a substitute for audited financial statements prepared in accordance with generally accepted accounting principles and are not necessarily indicative of the Company’s results for any future period.
Investment Will Improve Security of Future Pension Benefits for Union Associates & Reduce Financial Risk for the CompanyQUINCY, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Today Stop & Shop announced that its union locals have ratified an agreement to make a $667 million investment in pension benefits for union associates. “We’re extremely pleased that this agreement has been ratified across the board. By making this significant investment, we are doing the right thing for our associates who are dedicated to serving our customers every day,” said Gordon Reid, President, Stop & Shop.As part of the agreement, the following actions will occur: * Stop & Shop will end its participation the United Food & Commercial Workers International Union (UFCW) Industry Pension Fund, known as the “National Plan.” * Stop & Shop union associates will participate in a new variable benefit plan established by Stop & Shop, Kroger and the UFCW that is intended to sustainably provide future retirement benefits and reduce financial risk to the company.Stop & Shop’s agreement covers approximately 18,000 current Stop & Shop associates who are members of UFCW Locals 1445, 1449, 328, 371 and 464A.About Stop & ShopA neighborhood grocer for more than 100 years, today’s Stop & Shop is refreshed, reenergized and inspired, delivering convenient new solutions for customers. Committed to helping its communities enjoy better food and better lives, Stop & Shop has a longstanding history of giving back to the neighborhoods it serves with a focus on fighting hunger and pediatric cancer research and care. The Stop & Shop Supermarket Company LLC is an Ahold Delhaize USA Company and employs nearly 60,000 associates and operates over 400 stores throughout Massachusetts, Connecticut, Rhode Island, New York and New Jersey. To learn more about Stop & Shop, visit stopandshop.com. Media Contact: Jennifer Brogan Jennifer.firstname.lastname@example.org